Welcome to our dedicated page for Nakamoto SEC filings (Ticker: NAKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kindly MD, Inc. (NAKA) SEC filings page provides access to the company’s official regulatory disclosures as a publicly traded issuer. KindlyMD, a patient-first and healthcare data company with integrated healthcare services and a Bitcoin treasury strategy via its subsidiary Nakamoto Holdings Inc., uses filings with the U.S. Securities and Exchange Commission to report material events, corporate actions, and financial information.
Among the key documents available are Current Reports on Form 8-K, which the company uses to disclose significant developments. Recent 8-K filings have addressed topics such as the completion of the merger with Nakamoto, entry into and termination of material loan agreements secured by Bitcoin or other digital assets, authorization of a share repurchase program, receipt of a Nasdaq minimum bid price notice, and the establishment of dates and record dates for annual shareholder meetings. These filings also cover matters like redemption of a secured convertible debenture and the company’s financing arrangements with lenders focused on digital assets.
Investors can also review proxy materials, including the Definitive Proxy Statement on Schedule 14A, which outlines proposals submitted to stockholders, such as the election of directors, approval of converting Kindly MD from a Utah corporation to a Delaware corporation, ratification of the independent registered public accounting firm, and potential adjournment of the annual meeting. Notifications of late filing on Form 12b-25 (NT 10-Q) provide context when additional time is needed to complete quarterly reports, including explanations related to the accounting complexity of the merger with Nakamoto.
On Stock Titan, these filings are complemented by AI-powered tools that help summarize lengthy documents and highlight key points, such as new financing obligations, changes in capital structure, or updates on the company’s Bitcoin treasury strategy. Users can quickly locate information about quarterly and annual reporting, material agreements, shareholder votes, and listing status, as well as track how KindlyMD’s integrated healthcare operations and Bitcoin-focused activities are reflected in its regulatory record.
Nakamoto Inc. entered definitive all-stock merger agreements to acquire BTC Inc. and UTXO Management, expanding its Bitcoin-focused media, events and asset management platform. Nakamoto exercised its option under prior marketing agreements and will issue 336,804,102 shares of common stock for BTC and 26,785,714 shares for UTXO, both priced at $1.12 per share. Based on Nakamoto’s $0.2951 closing price on February 13, 2026, total consideration of 363,589,816 shares is valued at about $107.3 million, subject to customary purchase price adjustments and holdbacks. Independent and audit committee approvals were obtained, prior shareholder approval covers up to 600 million shares at $1.12, and key BTC and UTXO holders will be subject to six- and twelve‑month lock-ups after closing.
Nakamoto Inc. has a prospectus supplement covering up to 2,059,811 shares of common stock issuable upon exercise of previously issued warrants and 82,310 shares of common stock for resale. The company is not directly selling shares here; warrant holders and other stockholders may sell their shares using the Prospectus.
Nakamoto will receive cash only if the previously issued tradeable, non-tradeable and representative’s warrants from its June 3, 2024 initial public offering are exercised for cash. The supplement also attaches a Current Report on Form 8-K detailing a First Amendment to a Master Loan Agreement with Payward Interactive, Inc., allowing a designated trading wallet at the lender to be funded and pledged as collateral for both loan obligations and trading activity.
Nakamoto Inc. filed a current report outlining a change to its existing financing arrangement with Payward Interactive, Inc.. Through its subsidiary Nakamoto Holdings, the company entered into a First Amendment to its Master Loan Agreement. This amendment allows a designated trading wallet at Payward to be funded and formally designates that trading wallet as collateral.
The trading wallet will secure obligations under the Master Loan Agreement as well as any obligations that may arise from trading activity conducted through that wallet. The amendment itself is attached as an exhibit for full legal and operational details.
Nakamoto Inc. registers up to 2,059,811 shares of common stock issuable upon exercise of previously issued warrants and 82,310 shares of common stock for resale in a mixed primary and secondary offering. The primary component covers shares underlying tradeable, non-tradeable and representative’s warrants issued in the June 3, 2024 IPO, while the secondary component allows selling stockholders named in the base prospectus to sell their shares from time to time. The company is not directly selling common stock here and will receive no proceeds from investor resales, but may receive cash if outstanding warrants are exercised for cash. The supplement also incorporates recent 8-Ks, including the hiring of experienced finance leaders as Chief Financial Officer and Chief Accounting Officer, and a new 210,000,000 USDT loan from Kraken at an 8.00% annual fee, secured solely by Bitcoin collateral valued at not less than $323.4 million.
Nakamoto Inc., formerly known as Kindly MD, Inc., has formally rebranded its corporate identity. On January 16, 2026, the company filed a Certificate of Amendment in Delaware to change its name to Nakamoto Inc., effective January 21, 2026, and updated its principal office address to 300 10th Ave South, Nashville, TN 37203. The board also approved amended and restated bylaws to reflect the new name, with no other bylaw changes. The company’s common stock will continue trading on the Nasdaq Global Market under the symbol NAKA, and its tradeable warrants will continue to be quoted on the OTC Pink Market under the symbol NAKAW. Existing shareholders do not need to take any action as a result of this rebranding.
Kindly MD, Inc. reported the results of its annual stockholder meeting and approved a new share repurchase program. Stockholders elected Perianne Boring and Greg Xethalis as Class I directors to serve three-year terms. They also approved converting Kindly MD from a Utah corporation to a Delaware corporation, ratified Sadler, Gibb & Associates, LLC as independent auditor for the year ending December 31, 2025, and approved a potential adjournment of the meeting if additional votes were ever needed for key proposals.
The board approved a 2025 Repurchase Program authorizing the company to repurchase up to $10 million of its outstanding common stock through open market or privately negotiated transactions, including trades made under Rule 10b5-1 and Rule 10b-18 plans. The company entered into a Rule 10b-18 Repurchase Plan with TD Securities Inc., which will act as a non-exclusive agent to buy shares in the open market, earning a commission of $0.0075 per share repurchased.
Kindly MD, Inc. reported that it received a notice from Nasdaq that its common stock is not in compliance with the Nasdaq Global Market minimum bid price rule, because the closing bid has been below $1.00 per share for 30 consecutive business days.
The notice does not immediately affect trading, and the stock continues to trade on the Nasdaq Global Market under the symbol NAKA. Kindly MD has 180 calendar days, until June 8, 2026, to regain compliance by having its closing bid price at $1.00 per share or more for a minimum of 10 consecutive business days, with Nasdaq able to require up to 20 days. If the company cannot meet these requirements, it may apply to transfer to the Nasdaq Capital Market, pay a $5,000 application fee, and consider steps such as a reverse stock split. Failing compliance after the available periods could lead to its shares being subject to delisting, though the company could appeal.
Kindly MD, Inc. has filed a post-effective amendment to its automatic shelf registration to allow selling stockholders to resell up to 600,312,356 shares of common stock, covering PIPE shares, shares underlying pre-funded warrants, shares issuable upon conversion of convertible notes, and other previously issued securities. The company itself is not selling stock and will receive no proceeds from these resales.
The prospectus describes KindlyMD’s 2025 merger with Nakamoto Holdings, related PIPE transactions that raised approximately $540.0 million, and a $200.0 million convertible debt financing that has since been fully redeemed. It also notes an at-the-market program that permits issuances of up to $5 billion of additional common stock. The company outlines a strategy to use capital raising transactions to acquire and hold bitcoin as its primary treasury reserve asset while continuing its healthcare operations, and it emphasizes risks around stock price volatility and potential dilution.
Kindly MD, Inc. has filed a prospectus supplement covering the potential issuance of up to 2,059,811 shares of common stock upon exercise of previously issued tradeable, non-tradeable and representative warrants from its initial public offering, plus the resale of 82,310 existing shares by selling stockholders. The company is not selling any common stock itself, so all sale proceeds from resales will go to the warrant holders and selling stockholders, while the company would receive cash only if the warrants are exercised. The supplement also incorporates the company’s most recent Quarterly Report on Form 10-Q into the existing S-1 prospectus. Kindly MD’s common stock trades on Nasdaq under “NAKA” and its tradeable warrants under “NAKAW.”
Kindly MD, Inc. reported that it has released its financial results for the fiscal quarter ended September 30, 2025, through a press release. The company furnished this information in a current report under Item 2.02, which covers results of operations and financial condition, and attached the press release as Exhibit 99.1. Kindly MD’s common stock trades on The Nasdaq Stock Market under the symbol NAKA, and its tradeable warrants trade on the OTC Pink Market under NAKAW. The company is identified as an emerging growth company, and the report is signed by its Chief Executive Officer, David Bailey.